GLP-1 medicines are designed to act like this hormone while lasting longer in the body
Chronic oxidative stress thus contributes to insulin resistance development (Schattenberg et al
Thoughtful platforms highlight real success stories while avoiding sensationalism, promoting a culture that prizes enjoyment, pacing, and personal agency
These differences are usually small and dont meaningfully impact treatment
Finally, the study was conducted in Caucasian adults, limiting the findings generalizability to more diverse populations
However, there is still a significant difference between the WL that can be achieved with bariatric surgery and the currently approved obesity pharmacotherapies and there is heterogeneity in treatment responses with GLP-1 RA (for example people with T2D may achieve less WL compared to those without diabetes in clinical trials, despite similar lifestyle interventions) [13, 14]